行情

BBI

BBI

百视达
NASDAQ

实时行情|Nasdaq Last Sale

0.7350
+0.0047
+0.64%
盘后: 0.7300 -0.005 -0.68% 16:28 09/24 EDT
开盘
0.7290
昨收
0.7303
最高
0.7453
最低
0.7231
成交量
46.75万
成交额
--
52周最高
1.700
52周最低
0.4660
市值
6,314.79万
市盈率(TTM)
-0.9627
分时
5日
1月
3月
1年
5年
Brickell Biotech 将主持关于 DYRK1A 及其在自身免疫中的作用的关键意见领袖网络研讨会
Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other deb...
GlobeNewswire · 09/17 12:00
Brickell Biotech 将参加即将举行的 9 月会议
Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other deb...
GlobeNewswire · 09/08 12:30
Brickell 购买药物前景,增加新的首席营销官
Brickell Biotech Inc. (Nasdaq: BBI) has acquired a clinical-stage drug candidate and added a chief medical officer to its stable of C-suite senior executives.
University Wire · 09/02 03:13
Brickell Biotech 获得自身免疫性疾病候选药物的权利
Benzinga · 09/01 16:25
The Daily Biotech Pulse:默克发布双倍积极消息,安斯泰来自愿暂停基因治疗研究,Ascendis 产品
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 11:32
BRIEF-Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases
reuters.com · 09/01 11:29
Brickell Biotech 扩大领导团队,任命 Monica Luchi 博士为首席医疗官
Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell’s clinical development strategy and medical affairs functionsBOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or...
GlobeNewswire · 09/01 11:05
Brickell Biotech 获得针对自身免疫性和炎症性疾病的 1 期就绪 DYRK1A 抑制剂计划和新型平台的独家权利
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes rights to platform of
Benzinga · 09/01 11:01
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解BBI最新的财务预测,通过BBI每股收益,每股净资产,每股现金流等数据分析百视达近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测BBI价格均价为5.50,最高价位6.00,最低价为5.00。
EPS
机构持股
总机构数: 54
机构持股: 802.72万
持股比例: 9.34%
总股本: 8,591.54万
类型机构数股数
增持
8
192.79万
建仓
7
19.29万
减持
6
6.14万
平仓
5
16.94万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.13%
制药与医学研究
-1.02%
高管信息
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer
Albert Marchio
Chief Accounting Officer/Controller
Jose Breton
Chief Compliance Officer/General Counsel/Secretary
David McAvoy
Other
Deepak Chadha
Other
Adam Levy
Director
Gary Lyons
Director
Vijay Samant
Director
Dennison Veru
暂无数据
BBI 简况
Brickell Biotech Inc是一家处于临床阶段的制药公司。该公司专注于开发皮肤病的治疗方法。该公司的III期临床阶段研究产品候选药物sofpironium bromide是一种化学实体,属于一类称为抗胆碱能药的药物,用于治疗原发性腋窝(腋下)多汗症。该公司还开展针对各种皮肤病的早期研究项目。

微牛提供Brickell Biotech Inc(NASDAQ-BBI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BBI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BBI股票基本功能。